Bioorthogonal chemistry, already a workhorse of drug discovery research, prepares for the leap into human testing. Researchers at the Memorial Sloan Kettering Cancer Center in New York are preparing the first test in humans of a new type of diagnostic that combines a radioisotope and antibody via bioorthogonal ‘click’ chemistry. …

Tagworks reports that the scope of its proprietary click-to-release reaction can be expanded from the cleavage of carbamates to ethers, potentially allowing more drug types to be released from their click-cleavable ADCs. https://doi.org/10.1002/anie.201800402

Tagworks is featured in a BioCentury article on the state of the art and clinical prospects of in vivo click chemistry. https://www.biocentury.com/bc-innovations/tools-techniques/2017-06-15/new-use-click-chemistry-vivo-can-trigger-rapid-drug-?kwh=clear%3C%7C%3Eclears

In a recent publication in the scientific journal Bioconjugate Chemistry, Tagworks Pharma describes its success in using a bioorthogonal reaction for the selective cleavage of tumor-bound ADCs in mice. This represents a powerful new tool for ADC therapy as it does not rely on the currently used biological activation mechanisms, …

In a recent paper in the Journal of Nuclear Medicine, Tagworks, in collaboration with Austrialian biotech company Avipep, describes an alternative radioimmunotherapy strategy based on separate administration of the tumor-homing agent and a fast clearing radioactive probe. This way, the unwanted high renal retention of low-molecular weight radiometal tumor-homing agents can …

Developing an antibody tag with improved pharmacokinetics and stability allowed Tagworks to achieve increased tumor uptake of a radiolabeled pretargeting probe. Even though this adapted tag exhibited a slight loss in reactivity, its use in a antibody (CC49-TCO) conjugate demonstrated a longer clearance half-life, improved tumor accumulation and increased in …

Approaches that use in vivo chemistry to enable non-invasive molecular imaging and therapy are much sought after. Taking the recent achievements in pretargeted radioimmuno-imaging and -therapy in mice as a starting point, the Tagworks team discuss how the application scope of this approach can eventually be extended towards humans. Read …

Tagworks' pretargeting technology can boost tumor/non-tumor ratios compared with conventional radioimmunoimaging and -therapy. Published in Journal Nuclear Medicine 2013, 54, 11, 1989-1995 doi:10.2967/jnumed.113.12.3745

Antibody tags with 10-fold increased reactivity and enhanced in vivo stability - Check the paper on 'Highly reactive trans-cyclooctene tags with improved stability for Diels-Alder chemistry in living systems' published in Bioconjugate Chemistry 2013, 24 ,7, 1210-1217 doi:10.1021/bc400153y